1. Insurance implications of hereditary cancer findings

A. Risk classification vs discrimination

Insurers argue:

• Genetic mutations = measurable actuarial risk
• Higher risk justifies higher premiums or exclusions

Opponents argue:

• Genetic predisposition ≠ actual disease
• Using it creates “genetic discrimination”

So the legal question becomes:

Can insurers treat a healthy person with a genetic mutation as “already sick”?

B. Types of insurance affected

1. Health insurance

Most regulated:

• Many jurisdictions prohibit using genetic test results directly
• Prevents denial of coverage based only on mutation status

2. Life insurance

More controversial:

• Often allowed to consider genetic risk (depending on country)
• Can increase premiums or deny high-value policies

3. Disability insurance

• Insurers may argue future inability to work risk
• High scrutiny in courts due to livelihood impact

4. Long-term care insurance

• Heavily risk-rated in some systems
• Genetic data may significantly affect eligibility

C. Key legal tension

Three competing principles:

1. Actuarial fairness (pay according to risk)
2. Privacy of genetic data
3. Equality/non-discrimination rights

Courts often balance these rather than fully banning genetic use.

2. Important legal cases & precedents

CASE 1: Norman-Bloodsaw v. Lawrence Berkeley Laboratory (1998, USA)

Facts:

Employees were subjected to medical testing without informed consent, including tests that revealed genetic conditions (such as sickle cell trait and other predispositions). The employer’s lab shared this data internally.

Legal issue:

• Whether genetic testing without consent violates privacy and discrimination protections.

Court holding:

• The U.S. Court of Appeals held that non-consensual genetic and medical testing violated constitutional privacy rights and employment discrimination laws.

Importance for insurance context:

• Established that genetic information is highly protected personal data
• Even collection (not just use) can be unlawful without consent

Insurance implication:

Insurers using non-consensual genetic data could face similar privacy violations.

CASE 2: EEOC action against Burlington Northern Santa Fe Railway (2002 settlement, USA)

Facts:

Employees alleged the company secretly conducted genetic testing for carpal tunnel syndrome susceptibility after injury claims.

Outcome:

• Equal Employment Opportunity Commission (EEOC) intervened
• Company settled and agreed to stop genetic testing practices
• Paid damages (settlement, not admission of liability)

Legal principle:

• Genetic testing used to predict future injury risk in employment is discriminatory under ADA principles.

Insurance relevance:

• Strengthens argument that predictive genetic data cannot be used to penalize individuals for future risk
• Influences disability insurance underwriting standards

CASE 3: British Columbia Human Rights Tribunal cases on genetic discrimination (Canada, early 2000s onward)

Facts:

Several complaints involved insurers and employers requesting genetic test results or penalizing applicants based on family history of diseases like breast cancer.

Tribunal reasoning:

• Genetic predisposition is treated as “disability analog”
• Penalizing someone for a non-manifest condition violates equality protections

Legal principle:

• Protection extends beyond actual illness to perceived future disability

Insurance implication:

• Canadian insurers became more restricted in requesting genetic test results
• Emphasis on “manifest disease vs predicted disease”

CASE 4: UK Insurance Genetic Testing Moratorium (ABI agreement + regulatory oversight)

Nature:

Not a court case but a legally significant regulatory framework shaped by legal pressure.

Background:

• Concerns arose about insurers using BRCA and Huntington’s disease data
• Public fear of insurance exclusion

Outcome:

• UK insurers agreed to a moratorium:
  • Genetic test results generally cannot be used
  • Exception only for very high-value life insurance policies and limited conditions (approved genetic tests only)

Legal significance:

• Reflects balancing act between:
  • actuarial fairness
  • public health participation in genetic testing

Insurance implication:

• Encourages people to undergo genetic testing without fear of losing insurance access

CASE 5: International trend under GDPR (EU) and genetic data protection jurisprudence

Legal basis:

EU courts and regulators interpret genetic data as “special category data.”

Key legal principle:

• Genetic data = sensitive personal data requiring explicit consent
• Processing is heavily restricted unless strictly necessary

Insurance implication:

• Insurers in EU cannot freely access or require genetic test results
• Strong privacy barrier limits underwriting use

3. How these cases shape hereditary cancer insurance rules

Across jurisdictions, a common legal pattern emerges:

A. What insurers are usually allowed to use

• Family history (sometimes allowed)
• Clinical diagnosis (if disease is present)
• Age and lifestyle factors

B. What is often restricted

• Direct genetic test results (BRCA, Lynch syndrome)
• Mandatory genetic screening
• Coercion to disclose results

C. What courts tend to protect

• Individuals who are healthy but genetically at risk
• Privacy of predictive medical information
• Non-discrimination in employment-linked insurance schemes

4. Practical implications for hereditary cancer patients

If someone tests positive for BRCA or Lynch syndrome:

They may face:

• Higher premiums (life/disability insurance in some jurisdictions)
• Disclosure obligations depending on law
• Restrictions when applying for high-value policies

They are protected from:

• Health insurance denial in most regulated systems
• Forced genetic testing in employment contexts
• Broad public disclosure of genetic status